Ascendiant Capital reiterates Buy on Allarity Therapeutics; $11 target
Ascendiant Capital maintained a Buy rating on Allarity Therapeutics and kept a $11.00 price target, implying upside of 891.0% versus the Sep 15 close of $1.11.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.